Compare ABBV & PLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABBV | PLTR |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.9B | 433.2B |
| IPO Year | N/A | 2020 |
| Metric | ABBV | PLTR |
|---|---|---|
| Price | $229.95 | $181.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 19 |
| Target Price | ★ $242.28 | $171.74 |
| AVG Volume (30 Days) | 5.2M | ★ 35.6M |
| Earning Date | 01-30-2026 | 02-02-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 116.04 |
| EPS | ★ 1.32 | 0.43 |
| Revenue | ★ $59,644,000,000.00 | $3,896,163,000.00 |
| Revenue This Year | $10.38 | $56.55 |
| Revenue Next Year | $9.52 | $40.99 |
| P/E Ratio | ★ $174.80 | $426.61 |
| Revenue Growth | 7.40 | ★ 47.23 |
| 52 Week Low | $164.39 | $63.40 |
| 52 Week High | $244.81 | $207.52 |
| Indicator | ABBV | PLTR |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 48.17 |
| Support Level | $228.68 | $191.74 |
| Resistance Level | $232.02 | $196.35 |
| Average True Range (ATR) | 3.65 | 6.26 |
| MACD | 0.61 | -0.24 |
| Stochastic Oscillator | 81.21 | 19.46 |
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.